Blackstone Clarus III L.L.C.'s Net Worth

$358 Million

Who is Blackstone Clarus III L.L.C.?

Blackstone Clarus III L.L.C. has an estimated net worth of $358 Million. This is based on reported shares across multiple companies, which include Imago BioSciences, Inc., Talaris Therapeutics, Inc., Praxis Precision Medicines, Inc., ESSA Pharma Inc., GRAYBUG VISION, INC., Annexon, Inc., Forty Seven, Inc., Entasis Therapeutics Holdings Inc., and AVROBIO, Inc..

SEC CIK

Blackstone Clarus III L.L.C.'s CIK is 0001762202

Past Insider Trading and Trends

2021 was Blackstone Clarus III L.L.C.'s most active year for acquiring shares with 24 total transactions. Blackstone Clarus III L.L.C.'s most active month to acquire stocks was the month of April. 2021 was Blackstone Clarus III L.L.C.'s most active year for disposing of shares, totalling 16 transactions. Blackstone Clarus III L.L.C.'s most active month to dispose stocks was the month of April. 2020 saw Blackstone Clarus III L.L.C. paying a total of $7,400,000.00 for 12,461,583 shares, this is the most they've acquired in one year. In 2021 Blackstone Clarus III L.L.C. cashed out on 46,342,428 shares for a total of $0.00, their largest year based on trade value.